Three independent discounted-cash-flow-style models value iRadimed Corporation every trading day. 0 of 3 currently price IRMD above its market price.
| Free Cash Flow model | $30.25 |
| Excess Profit model | $37.46 |
| Residual Earnings model | $16.24 |
| Dividend Discount model | $14.63 |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +21.0% |
| Net debt / EBITDA | -1.8× |
| Gross margin | +76.7% |
| Revenue CAGR | +16.3% |
| Cash conversion | 1.1× |
| Dividend yield | +1.5% |
| Buyback yield | -0.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open IRMD in StockKitty